megamoolahjackpot| Microchip Biology: Application for Phase III clinical trial of cidabenide for the treatment of colorectal cancer accepted

News summary

[Microcore Biologymegamoolahjackpot: Application for a Phase III clinical trial of sidarabenamide in the treatment of colorectal cancer accepted] Securities Times e Company Newsmegamoolahjackpot, Microchip Biotech (688321) announced on the evening of May 12 that the company recently received a clinical trial for registration of domestically produced drugs issued by the Center for Drug Evaluation of the State Food and Drug Administration.megamoolahjackpot.megamoolahjackpot..

Newsletter text

[Microcore Biology: Application for Phase III clinical trial of Sidabenamide for colorectal cancer was accepted] Securities Times e Company News, Microchip Biotech (688321) announced on the evening of May 12 that the company recently received a notice issued by the Center for Drug Evaluation of the State Food and Drug Administration."Acceptance Notice" for registered clinical trials of domestically produced drugs, A randomized, open-label, controlled, multi-center, Phase III clinical trial of sidarabenamide in combination with cindimab and bevacizumab in the treatment of advanced microsatellite stable or complete mismatch repair (MSS/pMMR) colorectal cancer that failed ≥2 lines of standard treatment was accepted by the Center for Drug Evaluation of the State Food and Drug Administration.